{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:48:18Z","timestamp":1776829698795,"version":"3.51.2"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012479","name":"General Research Fund of Shanghai Normal University","doi-asserted-by":"publisher","award":["17122923"],"award-info":[{"award-number":["17122923"]}],"id":[{"id":"10.13039\/501100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012479","name":"General Research Fund of Shanghai Normal University","doi-asserted-by":"publisher","award":["17103322"],"award-info":[{"award-number":["17103322"]}],"id":[{"id":"10.13039\/501100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018247","name":"GOH Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001839","name":"University Grants Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001839","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.critrevonc.2025.105044","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:10:24Z","timestamp":1763827824000},"page":"105044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Chimeric antigen receptor-based cellular therapy for T-cell malignancies"],"prefix":"10.1016","volume":"217","author":[{"given":"Sile","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man Yan","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asif","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Kee","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shing","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson Yau Ki","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kee See","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwei","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.critrevonc.2025.105044_bib1","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","article-title":"How do cytotoxic lymphocytes kill cancer cells?","volume":"21","author":"Mart\u00ednez-Lostao","year":"2015","journal-title":"Clin. Cancer Res"},{"issue":"9-10","key":"10.1016\/j.critrevonc.2025.105044_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000525052","article-title":"Treatment with living drugs: pharmaceutical aspects of CAR T cells","volume":"107","author":"Holzinger","year":"2022","journal-title":"Pharmacology"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105044_bib3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105044_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105044_bib5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","article-title":"CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?","volume":"9","author":"Maciocia","year":"2025","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105044_bib6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"16","author":"Tan","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105044_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/PPO.0000000000000031","article-title":"CD19-CAR trials","volume":"20","author":"Ramos","year":"2014","journal-title":"Cancer J."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105044_bib10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105044_bib11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","volume":"12","author":"Pul\u00e8","year":"2005","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105044_bib13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"issue":"10297","key":"10.1016\/j.critrevonc.2025.105044_bib14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1158\/2643-3230.BCD-20-0093","article-title":"JPP. T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies","volume":"2","author":"van der Zwet","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105044_bib16","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2017-01-741389","article-title":"Introduction to the review series on T-cell malignancies","volume":"129","author":"Sehn","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105044_bib17","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105044_bib18","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2023021786","article-title":"A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas","volume":"144","author":"de Leval","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105044_bib19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4049\/jimmunol.152.2.517","article-title":"Expression and function of CD7 molecule on human natural killer cells","volume":"152","author":"Rabinowich","year":"1994","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105044_bib20","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood.V77.7.1546.1546","article-title":"Stages of T-Cell Receptor Protein Expression in T-Cell Acute Lymphoblastic Leukemia","volume":"77","author":"Campana","year":"1991","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.critrevonc.2025.105044_bib21","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105044_bib22","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s41375-023-01948-3","article-title":"Inserting EF1\u03b1-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection","volume":"37","author":"Jiang","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","article-title":"T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105044_bib24","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.4049\/jimmunol.160.12.5749","article-title":"Immunologic characterization of CD7-deficient mice","volume":"160","author":"Lee","year":"1998","journal-title":"J. Immunol."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.105044_bib25","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood.2021015020","article-title":"Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies","volume":"140","author":"Freiwan","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105044_bib26","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"30","key":"10.1016\/j.critrevonc.2025.105044_bib27","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial","volume":"39","author":"Pan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105044_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107731","article-title":"Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia","volume":"96","author":"Xie","year":"2021","journal-title":"Int Immunopharmacol."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105044_bib29","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105044_bib30","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105044_bib31","article-title":"Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity","volume":"5","author":"Ma","year":"2024","journal-title":"Cell Rep. Med"},{"issue":"97","key":"10.1016\/j.critrevonc.2025.105044_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adn6509","article-title":"CD5 deletion enhances the antitumor activity of adoptive T cell therapies","volume":"9","author":"Patel","year":"2024","journal-title":"Sci. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer Immunol. Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-024-01082-y","article-title":"Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control","volume":"14","author":"Lin","year":"2024","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105044_bib35","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105044_bib36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/138945009787354539","article-title":"Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma","volume":"10","author":"Frankel","year":"2009","journal-title":"Curr. Drug Targets"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105044_bib37","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2015.123711","article-title":"Resimmune, an anti-CD3\u03b5 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma","volume":"100","author":"Frankel","year":"2015","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.105044_bib38","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood.2023022455","article-title":"Targeting the TNF\/IAP pathway synergizes with anti-CD3 immunotherapy in T-cell acute lymphoblastic leukemia","volume":"143","author":"\u00c1vila \u00c1vila","year":"2024","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105044_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99442","article-title":"TCR\u03b1\u03b2\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy","volume":"3","author":"Rasaiyaah","year":"2018","journal-title":"JCI Insight"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105044_bib40","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/bloodadvances.2022008327","article-title":"Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma","volume":"7","author":"Watanabe","year":"2023","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105044_bib41","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.14.94","article-title":"Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas","volume":"6","author":"Remer","year":"2014","journal-title":"Immunotherapy"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.105044_bib42","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/1078-0432.CCR-19-2030","article-title":"FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and S\u00e9zary Syndrome","volume":"25","author":"Kasamon","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.105044_bib43","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.2147\/DDDT.S185896","article-title":"Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or S\u00e9zary Syndrome: Efficacy, Safety, and Patient Selection","volume":"14","author":"Blackmon","year":"2020","journal-title":"Drug Des. Devel Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105044_bib44","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ajh.24794","article-title":"Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies","volume":"92","author":"Perera","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105044_bib45","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood.V96.13.4046","article-title":"Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets","volume":"96","author":"Clemetson","year":"2000","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105044_bib46","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","article-title":"CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features","volume":"96","author":"Stein","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105044_bib47","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105044_bib48","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","article-title":"Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease","volume":"68","author":"D\u00fcrkop","year":"1992","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105044_bib49","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"32","key":"10.1016\/j.critrevonc.2025.105044_bib50","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105044_bib51","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J. Clin. Invest"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.105044_bib52","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas","volume":"132","author":"Scarf\u00f2","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105044_bib53","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","article-title":"AGS67E, an anti-CD37 monomethyl auristatin E antibody\u2013drug conjugate as a potential therapeutic for B\/T-cell malignancies and AML: a new role for CD37 in AML","volume":"14","author":"Pereira","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105044_bib54","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1182\/blood.2024024104","article-title":"Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies","volume":"144","author":"Frigault","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105044_bib55","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol. Rev."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105044_bib56","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105044_bib57","article-title":"Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism","volume":"5","author":"Huang","year":"2024","journal-title":"Cell Rep. Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105044_bib58","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41591-024-03326-7","article-title":"TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1\/2 trial","volume":"31","author":"Cwynarski","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0145-2126(98)00133-7","article-title":"Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines: suggestion for classification by immunophenotype and T-cell receptor studies","volume":"23","author":"Burger","year":"1999","journal-title":"Leuk. Res"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.105044_bib61","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","article-title":"Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia","volume":"133","author":"S\u00e1nchez-Mart\u00ednez","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-025-01715-0","article-title":"CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia","volume":"18","author":"Tirado","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105044_bib63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cyto.10003","article-title":"An approach to diagnosis of T-cell lymphoproliferative disorders by flow cytometry","volume":"50","author":"Gorczyca","year":"2002","journal-title":"Cytometry"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105044_bib64","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1038\/s41375-023-02039-z","article-title":"An \"off-the-shelf\" CD2 universal CAR-T therapy for T-cell malignancies","volume":"37","author":"Xiang","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105044_bib65","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105044_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007277","article-title":"Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells","volume":"11","author":"Fang","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105044_bib67","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1182\/blood-2023-180111","article-title":"Phase I First-in-Human Study on the Feasibility, Safety, and Antitumor Activity of CD4-Redirected Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with CD4+ T-Cell Malignancies (TCM)","volume":"142","author":"Assi","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105044_bib68","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \"off-the-shelf\" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105044_bib69","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","article-title":"Base-edited CAR T cells for combinational therapy against T cell malignancies","volume":"35","author":"Georgiadis","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105044_bib70","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105044_bib71","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1182\/blood-2024-203443","article-title":"CD7.Pebl-CART for Patients with Relapsed\/Refractory (r\/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL)","volume":"144","author":"Becilli","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105044_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","author":"Oh","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","article-title":"Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies","volume":"31","author":"Watanabe","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2025.105044_bib74","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.omto.2022.02.013","article-title":"Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody","volume":"24","author":"Ye","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"35","key":"10.1016\/j.critrevonc.2025.105044_bib75","doi-asserted-by":"crossref","first-page":"56219","DOI":"10.18632\/oncotarget.11019","article-title":"Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.105044_bib76","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1182\/blood-2023-184864","article-title":"Targeting T-Cell Lymphoma Using CD70-Directed Cord Blood-Derived CAR-NK Cells","volume":"142","author":"Rafei","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105044_bib77","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1027318530127","article-title":"CD4+ CD7\u2212 T cells: a separate subpopulation of memory T cells?","volume":"17","author":"Reinhold","year":"1997","journal-title":"J. Clin. Immunol."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105044_bib78","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.149819","article-title":"CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy","volume":"6","author":"Kim","year":"2021","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105044_bib79","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.105044_bib80","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/blood.V128.22.281.281","article-title":"Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR","volume":"128","author":"Lacey","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.105044_bib81","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.3389\/fimmu.2020.01965","article-title":"Use of Cell and Genome Modification Technologies to Generate Improved \"Off-the-Shelf\" CAR T and CAR NK Cells","volume":"11","author":"Morgan","year":"2020","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105044_bib82","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/mt.2015.104","article-title":"A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy","volume":"23","author":"Valton","year":"2015","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105044_bib83","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","article-title":"Long Terminal Repeat CRISPR-CAR-Coupled \"Universal\" T Cells Mediate Potent Anti-leukemic Effects","volume":"26","author":"Georgiadis","year":"2018","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105044_bib84","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/CJI.0000000000000413","article-title":"Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy","volume":"45","author":"Michaux","year":"2022","journal-title":"J. Immunother."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105044_bib85","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/bloodadvances.2017012823","article-title":"A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells","volume":"2","author":"Kamiya","year":"2018","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105044_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101462","article-title":"Optimization of hypo-alloimmunogenic multispecific CAR-T and SARS-CoV-2-specific T cells for off-the-shelf adoptive cell therapy","volume":"33","author":"Ng","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"30","key":"10.1016\/j.critrevonc.2025.105044_bib87","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial","volume":"39","author":"Pan","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105044_bib88","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management","volume":"27","author":"Li","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105044_bib89","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res."},{"issue":"6013","key":"10.1016\/j.critrevonc.2025.105044_bib90","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105044_bib91","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105044_bib92","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2025.105044_bib93","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fphar.2015.00021","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Glienke","year":"2015","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib94","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40164-024-00577-5","article-title":"Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies","volume":"13","author":"Zu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105044_bib95","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cpim.33","article-title":"Isolation and Functional Use of Human NKT Cells","volume":"119","author":"Exley","year":"2017","journal-title":"Curr. Protoc. Immunol."},{"issue":"5343","key":"10.1016\/j.critrevonc.2025.105044_bib96","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1126\/science.278.5343.1626","article-title":"CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides","volume":"278","author":"Kawano","year":"1997","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib97","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1365-2567.2000.00001.x","article-title":"CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes","volume":"100","author":"Exley","year":"2000","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib98","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","article-title":"CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy","volume":"23","author":"Hadiloo","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105044_bib99","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1172\/JCI37869","article-title":"Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages","volume":"119","author":"Song","year":"2009","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.critrevonc.2025.105044_bib100","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3389\/fimmu.2018.01266","article-title":"Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control","volume":"9","author":"Kinjo","year":"2018","journal-title":"Front Immunol."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.105044_bib101","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105044_bib102","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1172\/JCI83476","article-title":"CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo","volume":"126","author":"Tian","year":"2016","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.critrevonc.2025.105044_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1118681","article-title":"CAR-iNKT cells targeting clonal TCRV\u03b2 chains as a precise strategy to treat T cell lymphoma","volume":"14","author":"Rowan","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.105044_bib104","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3389\/fimmu.2017.00774","article-title":"Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy","volume":"8","author":"Gao","year":"2017","journal-title":"Front Immunol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105044_bib105","first-page":"1673","article-title":"Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells","volume":"21","author":"Schmidt-Wolf","year":"1993","journal-title":"Exp. Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105044_bib106","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1423167","article-title":"CD44v6 as innovative sarcoma target for CAR-redirected CIK cells","volume":"7","author":"Leuci","year":"2018","journal-title":"Oncoimmunology"},{"issue":"23","key":"10.1016\/j.critrevonc.2025.105044_bib107","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1158\/1078-0432.CCR-20-0357","article-title":"CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes","volume":"26","author":"Leuci","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.105044_bib108","first-page":"2587","article-title":"Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden","volume":"141","author":"Biondi","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105044_bib109","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.ymthe.2020.05.021","article-title":"Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System","volume":"28","author":"Rotiroti","year":"2020","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105044_bib110","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ccr.2014.07.026","article-title":"Targeted activation of human V\u03b39V\u03b42-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease","volume":"26","author":"Xiang","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib111","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/cmi.2012.43","article-title":"\u03b3\u03b4-T cells: an unpolished sword in human anti-infection immunity","volume":"10","author":"Zheng","year":"2013","journal-title":"Cell Mol. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105044_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102631","article-title":"Off-the-Shelf' Immunotherapy: Manufacture of CD8(+) T Cells Derived from Hematopoietic Stem Cells","volume":"10","author":"Boyd","year":"2021","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105044_bib113","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105044_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.729085","article-title":"\u03b3\u03b4 T Cells for Leukemia Immunotherapy: New and Expanding Trends","volume":"12","author":"Barros","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.105044_bib115","article-title":"mRNA-Engineered CD5-CAR-\u03b3\u03b4T(CD5-) Cells for the Immunotherapy of T-Cell Acute Lymphoblastic Leukemia","author":"Zhu","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib116","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41467-020-20658-3","article-title":"A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy","volume":"12","author":"Iriguchi","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105044_bib117","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/leu.2014.174","article-title":"Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity","volume":"29","author":"Chan","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2025.105044_bib118","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3389\/fimmu.2019.02361","article-title":"GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy","volume":"10","author":"Fern\u00e1ndez","year":"2019","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105044_bib119","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105044_bib120","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"issue":"6576","key":"10.1016\/j.critrevonc.2025.105044_bib121","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105044_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"issue":"7971","key":"10.1016\/j.critrevonc.2025.105044_bib123","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105044_bib124","article-title":"The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery","volume":"15","author":"Kularatne","year":"2022","journal-title":"Pharm. (Basel)"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105044_bib125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105044_bib126","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In Vivo Generation of CAR T Cells Selectively in Human CD4(+) Lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105044_bib127","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","article-title":"Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation","volume":"33","author":"Andorko","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2025.105044_bib128","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","author":"Hamilton","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"10500","key":"10.1016\/j.critrevonc.2025.105044_bib129","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105044_bib130","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.ymthe.2024.09.006","article-title":"Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed\/refractory T-ALL: A phase I trial","volume":"33","author":"Zhao","year":"2025","journal-title":"Mol. Ther."},{"issue":"7786","key":"10.1016\/j.critrevonc.2025.105044_bib131","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105044_bib132","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41587-024-02235-x","article-title":"Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens","volume":"43","author":"Walsh","year":"2025","journal-title":"Nat. Biotechnol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:33:26Z","timestamp":1773873206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":132,"alternative-id":["S1040842825004329"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105044","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor-based cellular therapy for T-cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105044"}}